Immunological and Clinical Changes in Allergic Asthmatics following Treatment with Omalizumab

IgE plays a key role in allergic asthma. We investigated whether omalizumab treatment of patients with moderate to severe allergic asthma leads to changes in inflammatory mediators and clinical symptoms. This sub-study was conducted on 35 patients with a positive skin prick test (SPT) requiring daily administration of beclomethasone dipropionate (500–1,000 µg), who participated in a multicentre, randomised, double-blind, placebo-controlled study. Omalizumab or placebo was administered at 0.016 mg/kg/IgE every 4 weeks. Patients recorded peak expiratory flow, asthma symptom score and β2-agonist use in daily diaries and spirometry was performed at each visit. β2-Agonist use and SPT wheal reaction decreased significantly (p < 0.05). Circulating levels of IL-5, IL-6, IL-8, IL-10, IL-13 and s-ICAM were measured before and after 16 weeks of treatment. IL-13 and s-ICAM were measured before and after 16 weeks of treatment. IL-13 decreased significantly (p < 0.01). IL-5 and IL-8 decreased in the omalizumab group compared to baseline. The other circulating mediators did not demonstrate any changes. Histamine release was significantly reduced (p < 0.01). Airway resistance (p < 0.05) and the provocative concentration inducing a 20% decrease in FEV1 (p < 0.05) were measured before, after 16 weeks, and 3 months after completion of treatment. Both parameters decreased significantly (p < 0.05). Peripheral eosinophil count decreased significantly compared to placebo (p < 0.01). These findings suggest that omalizumab has potential as a novel treatment for allergic asthma.

[1]  E. Matsui,et al.  OMALIZUMAB PROVIDES LONG-TERM CONTROL IN PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA , 2003 .

[2]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[3]  T. Haahtela,et al.  Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. , 2000, The Journal of allergy and clinical immunology.

[4]  J Crane,et al.  Prevalence and etiology of asthma. , 2000, The Journal of allergy and clinical immunology.

[5]  R. Bush,et al.  Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. , 1999, The New England journal of medicine.

[6]  P. Barnes.  Anti-IgE antibody therapy for asthma. , 1999, The New England journal of medicine.

[7]  A. Togias,et al.  Down-Regulation of Human Basophil IgE and FCεRIα Surface Densities and Mediator Release by Anti-IgE-Infusions Is Reversible In Vitro and In Vivo , 1999, The Journal of Immunology.

[8]  T. Mosmann,et al.  Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. , 1999, Journal of immunology.

[9]  R. Fick.  Anti-IgE as novel therapy for the treatment of asthma. , 1999, Current opinion in pulmonary medicine.

[10]  A. Togias,et al.  Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. , 1999, Journal of immunology.

[11]  D D Donaldson,et al.  Interleukin-13: central mediator of allergic asthma , 1998 .

[12]  Richard Beasley,et al.  Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC , 1998, The Lancet.

[13]  J. Schroeder,et al.  In vitro regulation of FcεRIα expression on human basophils by IgE antibody , 1998 .

[14]  J. Schroeder,et al.  In vitro regulation of FcepsilonRIalpha expression on human basophils by IgE antibody. , 1998, Blood.

[15]  C. Heusser,et al.  Therapeutic potential of anti-IgE antibodies. , 1997, Current opinion in immunology.

[16]  R. Dockhorn,et al.  Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. , 1997, The Journal of allergy and clinical immunology.

[17]  L. Boulet,et al.  Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. , 1997, American journal of respiratory and critical care medicine.

[18]  H. Boushey,et al.  The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. , 1997, American journal of respiratory and critical care medicine.

[19]  A. Togias,et al.  Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. , 1997, Journal of immunology.

[20]  J. Fox,et al.  Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. , 1996, The Journal of pharmacology and experimental therapeutics.

[21]  C. Dahinden,et al.  Human blood basophils produce interleukin-13 in response to IgE-receptor-dependent and -independent activation. , 1996, Blood.

[22]  L. Presta,et al.  Inhibition of allergic reactions with antibodies to IgE. , 1995, International archives of allergy and immunology.

[23]  J. Roca,et al.  Relationship between serum IgE and airway responsiveness in adults with asthma. , 1995, The Journal of allergy and clinical immunology.

[24]  J. Hooley,et al.  Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo. , 1994, Immunology.

[25]  F. Martinez,et al.  Association of asthma with serum IgE levels and skin-test reactivity to allergens. , 1989, The New England journal of medicine.

[26]  K. Ishizaka,et al.  Activation of mast cells for mediator release through IgE receptors. , 1984, Progress in allergy.

[27]  R. Siraganian.  Automated histamine release. A method for in vitro allergy diagnosis. , 1975, International archives of allergy and applied immunology.